Precipio, Inc. (PRPO)
Precipio, Inc. is a healthcare solutions company specializing in diagnostic products and services, particularly in blood cancer testing. Their proprietary technologies like ICE-COLD PCR aim to improve diagnostic accuracy and sensitivity.
Company Overview
Precipio, Inc. revolutionizes cancer diagnostics with innovative technologies like ICE-COLD PCR and HemeScreen, offering enhanced sensitivity and precision in blood cancer testing, positioning them as a key player in personalized medicine and bio-pharma collaborations within the healthcare sector.
Investment Thesis
Precipio, Inc. presents a compelling investment opportunity due to its innovative diagnostic technologies and strategic focus on blood cancer testing. The company's proprietary ICE-COLD PCR technology offers a significant advantage in terms of test sensitivity, potentially driving increased adoption and revenue growth. With a gross margin of 47.5%, Precipio has demonstrated its ability to generate profitable revenue from its diagnostic services and technology sales. Key growth catalysts include expanding collaborations with academic institutions and bio-pharma companies, as well as increasing market penetration of HemeScreen and IV-Cell products. While the company currently operates with a negative profit margin of -5.8% and a P/E ratio of -26.19, strategic partnerships and revenue growth from increased adoption of their technologies could drive profitability. The company's relatively small market cap of $0.04 billion suggests significant upside potential if Precipio can successfully execute its growth strategy and capitalize on the increasing demand for advanced diagnostic solutions.
Key Highlights
- Gross Margin of 47.5% demonstrates the potential for profitability in their diagnostic services and technology sales.
- ICE-COLD PCR technology enhances the sensitivity of molecular-based tests, offering a competitive advantage.
- Collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, positioning Precipio at the forefront of innovation.
- HemeScreen, a suite of genetic diagnostic panels, provides comprehensive analysis of blood cancers.
- Market Cap of $0.04B indicates significant growth potential if Precipio successfully executes its growth strategy.
Competitors
Strengths
- Proprietary ICE-COLD PCR technology.
- Specialized focus on blood cancer diagnostics.
- Collaborations with academic institutions.
- Comprehensive HemeScreen diagnostic panels.
Weaknesses
- Negative profit margin.
- Small market capitalization.
- Limited geographic reach.
- Reliance on a limited number of products.
Catalysts
- Ongoing: Expansion of collaborations with academic institutions for research and development.
- Ongoing: Increasing market penetration of HemeScreen diagnostic panels.
- Upcoming: Potential FDA approval of new diagnostic assays developed by Precipio.
- Ongoing: Sales growth of ICE-COLD PCR technology kits to bio-pharma companies.
Risks
- Ongoing: Competition from larger diagnostic companies with greater resources.
- Potential: Regulatory changes impacting the approval and reimbursement of diagnostic tests.
- Potential: Economic downturn affecting healthcare spending and demand for diagnostic services.
- Potential: Technological advancements rendering existing products obsolete.
- Ongoing: The company's negative profit margin poses a risk to its financial sustainability.
Growth Opportunities
- Expanding ICE-COLD PCR Technology Sales: Precipio has the opportunity to significantly increase revenue by expanding the sales of its ICE-COLD PCR technology kits to bio-pharma companies. The market for advanced PCR technologies is growing, driven by the increasing demand for highly sensitive diagnostic tools. By targeting bio-pharma companies involved in drug development and clinical trials, Precipio can capitalize on this trend and establish ICE-COLD PCR as a standard in molecular diagnostics. This expansion could generate substantial revenue growth within the next 2-3 years.
- Increasing HemeScreen Market Penetration: HemeScreen, Precipio's suite of genetic diagnostic panels for blood cancers, represents a significant growth opportunity. By increasing market penetration through targeted marketing and sales efforts, Precipio can capture a larger share of the blood cancer diagnostics market. The increasing prevalence of blood cancers and the growing demand for personalized treatment strategies will drive demand for HemeScreen. Success in this area could lead to significant revenue growth over the next 3-5 years.
- Strategic Collaborations with Academic Institutions: Precipio's collaborations with academic institutions specializing in cancer research, diagnostics, and treatment provide a strong foundation for future growth. By expanding these collaborations, Precipio can gain access to cutting-edge research, develop new diagnostic products, and strengthen its market position. These partnerships can also lead to increased adoption of Precipio's technologies and services within the academic community, driving revenue growth and enhancing the company's reputation over the long term.
- Geographic Expansion of Diagnostic Services: Precipio can pursue geographic expansion of its diagnostic services, particularly in regions with high unmet needs for advanced cancer diagnostics. By establishing partnerships with hospitals and clinics in new markets, Precipio can extend its reach and increase its customer base. This expansion could involve offering remote testing services or establishing local laboratories, depending on the specific market conditions. Successful geographic expansion could significantly increase Precipio's revenue and market share within the next 3-5 years.
- Development of New Diagnostic Assays: Precipio can leverage its expertise in molecular diagnostics to develop new diagnostic assays for other types of cancer and diseases. By expanding its product portfolio, Precipio can diversify its revenue streams and reduce its reliance on blood cancer testing. This could involve developing new PCR-based assays, as well as exploring other diagnostic technologies such as next-generation sequencing and liquid biopsy. Successful development and commercialization of new diagnostic assays could drive significant revenue growth over the long term.
Opportunities
- Expanding ICE-COLD PCR technology sales.
- Increasing HemeScreen market penetration.
- Developing new diagnostic assays.
- Geographic expansion of diagnostic services.
Threats
- Competition from larger diagnostic companies.
- Regulatory changes impacting diagnostic testing.
- Economic downturn affecting healthcare spending.
- Technological advancements rendering existing products obsolete.
Competitive Advantages
- Proprietary ICE-COLD PCR technology provides enhanced test sensitivity.
- Specialized expertise in blood cancer diagnostics.
- Collaborations with leading academic institutions.
- HemeScreen diagnostic panels offer comprehensive analysis.
About
Precipio, Inc., headquartered in New Haven, Connecticut, is a healthcare solutions company focused on transforming cancer diagnostics through innovative technologies and services. Founded with the mission to improve diagnostic accuracy and patient outcomes, Precipio has evolved into a provider of specialized diagnostic solutions, particularly in the field of hematological malignancies. The company's core offerings include diagnostic blood cancer testing services, leveraging proprietary technologies such as IV-Cell, a cell culture media enabling simultaneous culturing of four hematopoietic cell lineages, and HemeScreen, a suite of genetic diagnostic panels designed for comprehensive analysis of blood cancers. A key differentiator is their patented ICE-COLD PCR technology, which significantly enhances the sensitivity of molecular-based tests, allowing for earlier and more accurate detection of cancer. Precipio also offers COVID-19 antibody tests, demonstrating its adaptability to emerging healthcare needs. The company sells ICE-COLD-PCR technology kits to bio-pharma customers, further expanding its revenue streams and market reach. Through collaborations with leading academic institutions specializing in cancer research, diagnostics, and treatment, Precipio remains at the forefront of innovation in the diagnostic space, solidifying its position as a valuable partner in advancing personalized medicine.
What They Do
- Provides diagnostic blood cancer testing services.
- Offers IV-Cell, a proprietary cell culture media.
- Offers HemeScreen, a suite of genetic diagnostic panels.
- Provides ICE-COLD PCR, a patented specimen technology for increased test sensitivity.
- Sells ICE-COLD-PCR technology kits to bio-pharma customers.
- Offers COVID-19 antibody tests.
Business Model
- Sales of diagnostic products and reagents, including IV-Cell and HemeScreen.
- Revenue from diagnostic testing services, particularly in blood cancer diagnostics.
- Sales of ICE-COLD-PCR technology kits to bio-pharma companies.
- Collaborations with academic institutions for research and development.
Industry Context
Precipio, Inc. operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in personalized medicine and increasing demand for accurate and early disease detection. The market for cancer diagnostics is particularly robust, fueled by rising cancer incidence rates and the need for more effective treatment strategies. Precipio's focus on blood cancer testing positions it within a specialized segment of this market. Competitors include companies like APUS, INTS, ITRM, LDDD, and MLSS, each offering various diagnostic solutions. Precipio differentiates itself through its proprietary technologies, such as ICE-COLD PCR, which enhances test sensitivity and provides a competitive edge in the market.
Key Customers
- Hospitals and clinics requiring diagnostic testing services.
- Academic institutions involved in cancer research.
- Bio-pharma companies utilizing ICE-COLD PCR technology for drug development.
- Patients seeking diagnostic testing for blood cancers.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6M | $-79,000 | $-0.05 |
| Q2 2025 | $6M | $74,000 | $0.05 |
| Q1 2025 | $4M | $-884,000 | $-0.59 |
| Q4 2024 | $5M | $-365,000 | $-0.24 |
Source: Company filings
Chart & Info
Price Chart
Precipio, Inc. (PRPO) stock price: $23.74 (-0.08, -0.34%)
Why Bull
- •Recent insider buying suggests confidence in Precipio's future, indicating that key stakeholders believe in the company's growth potential.
- •Community sentiment has shifted positively with discussions highlighting new product developments and their potential impact on market share.
- •Analysts have noted an increase in partnerships, which could enhance Precipio's service offerings and broaden its customer base.
- •The overall market perception is improving as investors look for innovative companies in the healthcare sector, positioning Precipio favorably.
Why Bear
- •Concerns about the competitive landscape persist, with some investors worried that established players may overshadow Precipio's growth.
- •Recent social sentiment has shown skepticism regarding the company's ability to scale effectively, raising doubts among retail investors.
- •There are ongoing discussions about cash flow challenges, which could hinder operational growth and limit strategic investments.
- •Market analysts have pointed out that while there are positive developments, they may not be enough to offset the risks associated with Precipio's business model.
Latest News
No recent news available for PRPO.
Technical Analysis
Rationale
AI-generated technical analysis for PRPO including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Precipio, Inc. (PRPO) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for PRPO.
Make a Prediction
Set your price target for Precipio, Inc. (PRPO), choose a timeframe, and track your prediction accuracy.
Current price: $23.74
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PRPO.
Price Targets
Wall Street price target analysis for PRPO.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 6.4% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 8/100
Gross margin at 44.8% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates PRPO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Frequently Asked Questions
What does Precipio, Inc. do?
Precipio, Inc. is a healthcare solutions company that specializes in diagnostic products, reagents, and services, primarily focused on blood cancer testing. The company offers a range of diagnostic solutions, including IV-Cell, a proprietary cell culture media, HemeScreen, a suite of genetic diagnostic panels, and ICE-COLD PCR, a patented technology that enhances the sensitivity of molecular-based tests. Precipio sells ICE-COLD-PCR technology kits to bio-pharma customers and collaborates with academic institutions to advance cancer research and diagnostics. Their business model revolves around providing innovative diagnostic tools and services to improve patient outcomes in the field of hematological malignancies.
Is PRPO stock a good buy?
PRPO stock presents a speculative investment opportunity with high potential upside and significant risks. The company's innovative ICE-COLD PCR technology and focus on blood cancer diagnostics offer a competitive advantage. However, the company's negative profit margin and small market capitalization raise concerns about its financial stability. Investors should carefully consider Precipio's growth potential, technological advantages, and financial risks before investing. Monitoring key metrics such as revenue growth, gross margin, and progress in expanding collaborations will be crucial in assessing the investment's viability. A positive shift towards profitability would be a strong indicator of future success.
What are the main risks for PRPO?
Precipio faces several key risks, including intense competition from larger diagnostic companies with greater resources, potential regulatory changes impacting the approval and reimbursement of diagnostic tests, and the risk of an economic downturn affecting healthcare spending. Additionally, technological advancements could render Precipio's existing products obsolete, requiring continuous innovation and investment in research and development. The company's current negative profit margin also poses a significant risk to its financial sustainability, requiring effective cost management and revenue growth strategies to achieve profitability. Successfully navigating these risks will be crucial for Precipio's long-term success.
Is PRPO a good stock to buy?
Whether PRPO is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the PRPO MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is PRPO data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for PRPO?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Precipio, Inc..
Who are PRPO's main competitors?
Precipio, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how PRPO compares.
What do analysts say about PRPO?
Analyst ratings and price targets for PRPO are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is PRPO's market cap?
Market capitalization reflects the total market value of PRPO's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has PRPO stock performed recently?
Check the Chart & Info tab for PRPO's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in PRPO?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for PRPO-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling PRPO?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for PRPO.
Is PRPO a good stock for beginners?
Precipio, Inc. (PRPO) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is PRPO for first-time investors?
Every stock carries risk, including Precipio, Inc. (PRPO). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like PRPO.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Future performance is subject to market conditions and company-specific factors.